Adapting to the Challenge COVID-19 Presents to Create a New Biopharma Normal

In a recent Forbes article, Danaher’s Chief Science officer, Jose-Carlos Gutierrez-Ramos, described the impact of the COVID-19 pandemic as follows:“I believe the biopharma business model has fundamentally changed.